Donald Landry

Last updated
Donald W. Landry
CitizenshipUnited States
Known forStem cell and artificial enzyme research
SpouseMaureen O'Reilly-Landry
Awards Presidential Citizens Medal

Donald W. Landry is an American scientist who is the Hamilton Southworth Professor of Medicine, Chair of the Department of Medicine at Columbia University and Physician-in-Chief at NewYork-Presbyterian Hospital/Columbia University Irving Medical Center since 2008. He is also past founding director of the Division of Experimental Therapeutics, and past director of the Division of Nephrology. Landry completed his Ph.D. in organic chemistry with R.B. Woodward at Harvard University in 1979 and then obtained the M.D. degree from Columbia University in 1983. After completing his residency in internal medicine at the Massachusetts General Hospital/Harvard Medical School, he returned to Columbia for training as an NIH Physician-Scientist, 1985–90, and has remained as a member of the Columbia faculty. [1] [2]

Contents

Personal life

His wife, Maureen, is a clinical psychologist and psychoanalyst. [3] [4] They have two sons, Christopher and Michael.[ citation needed ] He is the oldest of 4, having 3 younger brothers, Robert, Thomas and John.

Work and achievements

Landry directed the Doris Duke Clinical Research Fellowship Program's Columbia site and co-directed the Advanced Pathophysiology course for 4th-year medical students at the Columbia College of Physicians and Surgeons, both for over a decade. [5] Landry was a member of the President's Council on Bioethics and is co-chair of the Witherspoon Council for Ethics and the Integrity of Science. [1] [6] He is a founder of Tonix Pharmaceuticals (NASDAQ: TNXP), [7] a member of the Board of Directors of Sensient Technologies, and chair of the scientific advisory board of Applied Therapeutics, Inc., which was founded based on his patents and now trades on NASDAQ. [8] [9] He is co-founder of Tegrigen Therapeutics, a biotech start-up focused on integrin targets.

Landry was elected to membership of the American Society for Clinical Investigation and the Association of American Physicians. [10] [11] He is listed in Who's Who in the World and in 2015 was inducted at the Smithsonian as an elected Fellow of the National Academy of Inventors. [12] [13] Landry received the Presidential Citizens Medal, the nation's second-highest civilian honor, from President George W. Bush at the Oval Office in 2008 "for diverse and pioneering research and his efforts to improve the well-being of his fellow man." [14]

Research

Landry has focused on novel approaches to intractable health problems, combining medicine and organic chemistry. His work on cocaine addiction led to the discovery of an artificial enzyme to degrade cocaine. His report on the enzyme, published in Science, was chosen by the American Chemical Society as one of the 25 most important chemistry papers in the world for 1993. [15] [16] An agent (Cocaine esterase) he co-developed to treat cocaine overdose has entered clinical trials from Tonix Pharmaceuticals. [17] [18] [19] He founded the Columbia Organic Chemistry Collaborative Center and it is through this Center that he conducts his current work on drug discovery. [20]

Landry discovered a new hormone deficiency syndrome: vasopressin deficiency in vasodilatory shock. In pioneering the use of vasopressin to treat septic shock and vasodilatory shock after cardiopulmonary bypass, he changed clinical practice for these life-threatening conditions. He also founded ICU nephrology at Columbia, introducing continuous renal replacement therapy to treat renal failure in patients with shock. [21]

Landry developed an alternative method for the production of human embryonic stem cells that relies on harvesting live, normal cells from embryos that—by objective, peer-reviewed criteria—have died of natural causes. Cells harvested from dead embryos would be covered under the established ethics governing transplantation of essential organs from deceased donors. [22]

Related Research Articles

Nephrology is a specialty for both adult internal medicine and pediatric medicine that concerns the study of the kidneys, specifically normal kidney function and kidney disease, the preservation of kidney health, and the treatment of kidney disease, from diet and medication to renal replacement therapy. The word "renal" is an adjective meaning "relating to the kidneys", and its roots are French or late Latin. Whereas according to some opinions, "renal" and "nephro" should be replaced with "kidney" in scientific writings such as "kidney medicine" or "kidney replacement therapy", other experts have advocated preserving the use of renal and nephro as appropriate including in "nephrology" and "renal replacement therapy", respectively.

Internal medicine, also known as general internal medicine in Commonwealth nations, is a medical specialty for medical doctors focused on the prevention, diagnosis, and treatment of internal diseases in adults. Medical practitioners of internal medicine are referred to as internists, or physicians in Commonwealth nations. Internists possess specialized skills in managing patients with undifferentiated or multi-system disease processes. They provide care to both hospitalized (inpatient) and ambulatory (outpatient) patients and often contribute significantly to teaching and research. Internists are qualified physicians who have undergone postgraduate training in internal medicine, and should not be confused with "interns", a term commonly used for a medical doctor who has obtained a medical degree but does not yet have a license to practice medicine unsupervised.

<span class="mw-page-title-main">Vasopressin</span> Mammalian hormone released from the pituitary gland

Human vasopressin, also called antidiuretic hormone (ADH), arginine vasopressin (AVP) or argipressin, is a hormone synthesized from the AVP gene as a peptide prohormone in neurons in the hypothalamus, and is converted to AVP. It then travels down the axon terminating in the posterior pituitary, and is released from vesicles into the circulation in response to extracellular fluid hypertonicity (hyperosmolality). AVP has two primary functions. First, it increases the amount of solute-free water reabsorbed back into the circulation from the filtrate in the kidney tubules of the nephrons. Second, AVP constricts arterioles, which increases peripheral vascular resistance and raises arterial blood pressure.

<span class="mw-page-title-main">Cilostazol</span> Chemical compound

Cilostazol, sold under the brand name Pletal among others, is a medication used to help the symptoms of intermittent claudication in peripheral vascular disease. If no improvement is seen after 3 months, stopping the medication is reasonable. It may also be used to prevent stroke. It is taken by mouth.

<span class="mw-page-title-main">Carol Davila University of Medicine and Pharmacy</span> University in Bucharest, Romania

Carol Davila University of Medicine and Pharmacy or University of Medicine and Pharmacy Bucharest, commonly known by the abbreviation UMFCD, is a public health sciences university in Bucharest, Romania. It is one of the largest and oldest institutions of its kind in Romania. The university uses the facilities of over 20 clinical hospitals all over Bucharest.

Allied Academies is a reportedly fraudulent corporation chartered under the laws of North Carolina. Its postal address is in London, United Kingdom. It presents itself as an association of scholars, with supporting and encouraging research and the sharing and exchange of knowledge as its stated aims. The organization consists of 30 affiliate academies, which provide awards to academics and publish academic journals both online and in hard copy for members. Since 2015 the organization has been listed on Jeffrey Beall's list of "potential, possible, or probable predatory scholarly open-access publishers". It is in a partnership with OMICS Publishing Group which uses its website and logo. In 2018, OMICS owner Srinubabu Gedela declared that he had informed the Nevada court that Allied Academies was a subsidiary of OMICS International. During a conference in 2018, they falsely listed a prominent chemist among its organizing committee who had not agreed to this and was not affiliated with Allied Academies.

<span class="mw-page-title-main">Gombe State University</span> Public university in Nigeria

Gombe State University (GSU) is located in Tudun Wada, an area in Shamaki Ward, Gombe, Gombe State, Nigeria. It is located in the Northern part of Nigeria. It is a member of the Association of Commonwealth Universities. The state university has a Chancellor and 11-members of the governing council, as well as principal officers and management staff. Abdullahi Mahadi was the first vice chancellor of the university.

<span class="mw-page-title-main">Michael R. Hayden</span>

Michael R. Hayden, is a Killam Professor of Medical Genetics at the University of British Columbia, the highest honour UBC can confer on any faculty member. Only four such awards have ever been conferred in the Faculty of Medicine. Dr. Hayden is also Canada Research Chair in Human Genetics and Molecular Medicine. Hayden is best known for his research in Huntington disease (HD).

<span class="mw-page-title-main">Seth Lederman</span> American pharmacologist (born 1957)

Seth Lederman is an American physician, scientist and specialty pharmaceuticals entrepreneur. He is a co-founder and the current President and Chairman of Tonix Pharmaceuticals, a specialty pharmaceutical product development and commercialization company.

<span class="mw-page-title-main">Selepressin</span> Chemical compound

Selepressin (INN), also known as [Phe(2),Ile(3), Hgn(4),Orn(iPr)(8)]vasopressin) is a potent, highly selective, short-acting peptide full agonist of the vasopressin 1A receptor and analog of vasopressin which was under development by Ferring Pharmaceuticals for the treatment of vasodilatory hypotension in septic shock.

<span class="mw-page-title-main">Tonix Pharmaceuticals</span> Commercial pharmaceutical company

Tonix Pharmaceuticals is a pharmaceutical company based in Chatham, New Jersey that focuses on repurposed drugs for central nervous system conditions and as of 2020 was also pursuing a vaccine for COVID-19 and a biodefense project.

<span class="mw-page-title-main">Vasopressin (medication)</span> Chemical compound

Vasopressin infusions are in use for septic shock patients not responding to fluid resuscitation or infusions of catecholamines to increase the blood pressure while sparing the use of catecholamines. These argipressins have much shorter elimination half-life than synthetic non-arginine vasopresines with much longer elimination half-life of many hours. Further, argipressins act on V1a, V1b, and V2 receptors which consequently lead to higher eGFR and lower vascular resistance in the lungs. A number of injectable arginine vasopressins are in clinical use in the United States and the European Union. Pitressin among others, is a medication most commonly used in the treatment of frequent urination, increased thirst, and dehydration such as that resulting from diabetes insipidus, which causes increased and diluted urine. It is used to treat abdominal distension following some surgeries, and in stomach roentgenography. Vasopressin is a hormone that affects the kidneys and reduces urine flow.

CSL Vifor is a global specialty pharmaceuticals company in the treatment areas of iron deficiency, dialysis, nephrology & rare disease. It is headquartered in Switzerland and consists of CSL Vifor, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Sanifit Therapeutics.

<span class="mw-page-title-main">Angiotensin II (medication)</span> Medication for low blood pressure

Angiotensin II is a medication that is used to treat hypotension resulting from septic shock or other distributive shock. It is a synthetic vasoconstrictor peptide that is identical to human hormone angiotensin II and is marketed under the brand name Giapreza. The Food and Drug Administration approved the use of angiotensin II in December 2017 to treat low blood pressure resulting from septic shock.

Vasodilatory shock, vasogenic shock, or vasoplegic shock is a medical emergency belonging to shock along with cardiogenic shock, septic shock, allergen-induced shock and hypovolemic shock. When the blood vessels suddenly relax, it results in vasodilation. In vasodilatory shock, the blood vessels are too relaxed leading to extreme vasodilation and blood pressure drops and blood flow becomes very low. Without enough blood pressure, blood and oxygen will not be pushed to reach the body's organs. If vasodilatory shock lasts more than a few minutes, the lack of oxygen starts to damage the body's organs. Vasodilatory shock like other types of shock should be treated quickly, otherwise it can cause permanent organ damage or death as a result of multiple organ dysfunction.

<span class="mw-page-title-main">Sangivamycin</span> Chemical compound

Sangivamycin is a natural product originally isolated from Streptomyces rimosus, which is a nucleoside analogue. It acts as an inhibitor of protein kinase C. It has antibiotic, antiviral and anti-cancer properties and has been investigated for various medical applications, though never approved for clinical use itself. However, a number of related derivatives continue to be researched.

Scott A. Waldman is an MD and biomedical scientist at Sidney Kimmel Medical College of Thomas Jefferson University, where he is the Samuel M.V. Hamilton Professor of Medicine, and also tenured professor and chair of the Department of Pharmacology & Experimental Therapeutics. He is author of a pharmacology textbook, and former chief editor of Clinical Pharmacology & Therapeutics. He is known for his work in atrial natriuretic factor intracellular signaling through guanylate cyclase (GC), and the relation of Guanylyl cyclase C (GC-C) to the pathogenesis of colorectal cancer. Also for his hypotheses concerning the roles of intestinal paracrine hormones in satiety, obesity and cancer risk. Waldman also holds a concurrent position as adjunct professor at the University of Delaware, School of Health Sciences.

Richard B. Gaynor is an American physician specializing in hematology-oncology, educator, drug developer, and business executive. He served as an Associate Professor of Medicine at UCLA School of Medicine for nearly a decade, and subsequently as an endowed Professor of Medicine and Microbiology at the University of Texas Southwestern Medical School prior to joining the pharmaceutical industry in 2002. His research on NF-κB, IκB kinase, and other mechanisms regulating viral and cellular gene expression has been covered in leading subject reviews. He has been a top executive at several pharmaceutical companies, with respect to the development and clinical testing of novel anticancer drugs and cell therapies. For over a decade and a half, he worked at Eli Lilly and Company, where he became the Senior Vice President of Oncology Clinical Development and Medical Affairs in 2013. Gaynor was President of R&D at Neon Therapeutics from 2016 to 2020, when he became the President of BioNTech US, both pharmaceutical companies headquartered in Cambridge, MA. His honors include being elected a member of the American Society for Clinical Investigation, and the Association of American Physicians.

References

  1. 1 2 "The President's Council on Bioethics: William B. Hurlbut, M.D." bioethicsarchive.georgetown.edu. Retrieved 2022-03-09.
  2. "Donald W. Landry, MD, Nephrology - at CUIMC/Presbyterian Hospital and Vanderbilt Clinic". doctors.columbia.edu. Retrieved 2022-03-09.
  3. "Maureen O'Reilly-Landry, PhD". columbiapsychiatry.org. 9 February 2017.
  4. "Our Team". Resilience and Covid. Retrieved 2022-03-09.[ permanent dead link ]
  5. "Columbia University College Of Physicians & Surgeons Selected To Participate In Doris Duke Clinical Research Fellowship Program". Columbia University Irving Medical Center. 2000-12-15. Retrieved 2022-03-09.
  6. "The Witherspoon Council on Ethics and the Integrity of Science". www.witherspooncouncil.org. Retrieved 2022-03-09.
  7. "Tonix Pharmaceuticals Holding Corp (TNXP) Stock Price & News - Google Finance". www.google.com. Retrieved 2022-10-31.
  8. "SXT Company Profile & Executives - Sensient Technologies Corp. - Wall Street Journal". www.wsj.com. Retrieved 2022-03-09.
  9. "Donald Landry". Applied Therapeutics. Retrieved 2022-03-09.[ permanent dead link ]
  10. "The American Society for Clinical Investigation". Archived from the original on 2022-10-18. Retrieved 2022-03-09.
  11. "Association of American Physicians". aap-online.org. Retrieved 2022-03-09.
  12. "National Academy of Inventors" . Retrieved 2022-03-09.
  13. Perruso, Alison (2014). Who's Who in the World 2015. Marquis Who's Who. ISBN   978-0837911540.
  14. "Dr. Donald Landry Honored With Presidential Citizens Medal | NYP". www.nyp.org. Retrieved 2022-03-09.
  15. Landry, Donald W. (1993). "Antibody-catalyzed degradation of cocaine". Science. 259 (5103): 1899–1901. Bibcode:1993Sci...259.1899L. doi:10.1126/science.8456315. PMID   8456315.
  16. "Donald Landry Named P&S Chair Of Medicine". Columbia University Irving Medical Center. 2008-11-05. Retrieved 2022-03-09.
  17. "Overdose Research Grant Awarded To Chatham-Based Pharma Company". Chatham, NJ Patch. 2022-07-26. Retrieved 2022-10-31.
  18. "The Prospects for TNX-1300, a Drug to Reverse Cocaine Overamps". Filter. 2022-09-02. Retrieved 2022-10-31.
  19. Tonix Pharmaceuticals, Inc. (2022-06-23). "An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects".{{cite journal}}: Cite journal requires |journal= (help)
  20. "Organic Chemistry Collaborative Center (OCCC)". Vagelos College of Physicians and Surgeons. 2018-11-28. Retrieved 2022-03-09.
  21. Landry, Donald W. (1997). "Vasopressin deficiency contributes to the vasodilation of septic shock". Circulation. 95 (5): 1122–1125. doi:10.1161/01.CIR.95.5.1122. PMID   9054839.
  22. Landry, Donald W. (2004). "Embryonic death and the creation of human embryonic stem cells". Journal of Clinical Investigation. 114 (9): 1184–1186. doi:10.1172/JCI23065. PMC   524233 . PMID   15520846.